[ad_1]
In the meantime, many patients use digital support in everyday life in the form of special diabetic applications, as well as technical innovations such as insulin pumps and continuous glucose monitoring systems. The first "Hybrid Closed Loop" system, which controls the measurement of blood glucose levels and the necessary administration of insulin as much as possible, will be available in Europe at the end of this year.
Daily blood glucose measurements and customized insulin doses are associated with high costs for diabetic patients. To better adapt their metabolism, many patients use insulin pumps and continuous glucose monitoring systems. "Blood sugar is regularly measured automatically, and patients can then deliver an appropriate dose of insulin with an insulin pump," explains dr. Med. Matthias Kaltheuner, a member of the German Diabetes Society Committee. "These technologies make everyday life easier for patients," says a resident diabetic. Glucose sensor technology provides a much more accurate insight into the metabolic status and possible effects through food intake, movement, mood swings and other diseases.
Using the "closed loop" system, which will be available this autumn in selected EU countries, patients with diabetes will gain more independence / flexibility in therapy. The system connects the insulin pump to the sensor for continuous glucose measurement in the subcutaneous fat tissue, a blood glucose meter for calibrating the sensor, and a computer program that automatically controls the insulin pump ("hybrid" system). "The interaction of all technologies allows the automatic delivery of insulin. The patient is thus saving the calculation of the required dose of insulin," says professor dr med. Med. Jens Aberle, president of the 12th conference on diabetes in the fall. "In addition, the patient's metabolism is improving and the risk of excessive and hypoglycaemia is reduced," said the head of the Department of Endocrinology and Diabetology at the Hamburg-Eppendorf University Hospital.
A randomized comparative study recently published in the journal The Lancet has shown that the closed system is superior to the sensory therapy in clinical use. The study covered 86 patients with type 1 diabetes, aged six to 65 years, who had a suboptimal blood sugar level despite the use of an insulin pump. While half of the volunteers were equipped with continuous blood glucose monitoring devices, next to the insulin pump, the other half received a closed loop system. Result: Patients using the hybrid closed loop system were able to maintain blood glucose significantly longer in a predetermined target range compared to patients with therapy with the sensor, where the insulin dose was injected and injected. This is especially true during the night (2).
"Technological progress in the treatment of diabetes provides great added value to those affected. They release patients from vital tasks and thus promote the quality of life," stresses the president of DDG dr. Med. Med. Dirk Muller-Vieland. Opens new opportunities for both the patient and the doctor, as well as exchanges, which could deepen the relationships between doctors and patients and improve care.
From 9 to 10 November, about 3800 participants discussed new scientific knowledge on the development, prevention and treatment of diabetes mellitus and obesity at the Congress Center RheinMain Viesbaden under the motto "Interdisciplinary Care – A Patient at the Center". "In addition to technology and digitization, new conference conferences were also the focus of the conference," explains Managing Director of DDG Barbara Bitzer. "We are pleased that the participants especially received topics such as digitization and new technologies". Because diabetes is a disease model for the entire health care system for the significant use of digitization.
sources:
(1) Jacobs E, Rathmann V (2017): Epidemiology of Diabetes in Germany. In: German report on the health status of diabetes 2019. Inventory.
(2) Tauschmann M et al (2018): Delivery of a closed loop of insulin in suboptimal-controlled type 1 diabetes: a multicentric, 12-week randomized test; Lancet (2018); online first; DOI: https: //doi.org/10.1016/S0140-6736 (18) 31947-0
idv 2018/11
Source link
